HUM 10-K Analysis: Why Only 28% of Humana's Cash Flow Collapse Has a Clear Cause

Humana, the Medicare Advantage insurer serving over 5 million seniors, grew revenue 10.1% to $129.7 billion in FY2025 — and saw operating cash flow collapse 69% to $921 million. Management calls it "timing." The 10-K data tells a more complicated story.

The headline numbers look like a health insurance company navigating a difficult year. Premium revenue rose 9.6% to $122.8 billion, driven by the Inflation Reduction Act's higher per-member subsidies. Approximately 93% of Humana's revenue comes from government-sponsored programs — primarily Medicare Advantage plans funded by CMS capitation payments — where the company earns the spread between premiums received and benefits paid. At a 90.2% benefit ratio and 12.0% operating cost ratio, Humana operates on razor-thin margins, with a net margin of just 0.92%.

But the 10-K, filed February 19, 2026, reveals why that revenue growth is masking a deeper deterioration. Accounts receivable explain only 28% of the $2.05 billion cash flow decline. Q4 2025 quietly ran at an estimated 106.6% combined ratio — meaning the company was losing money on insurance operations in the final quarter. Star Ratings plunged from 94% to approximately 20% of members in 4+ star plans, creating a roughly $3.5 billion revenue headwind for 2026. And the only structural bright spot — CenterWell's 5.96% margin engine — would need to roughly double its operating income just to offset the Star Ratings loss.

The Cash Flow Illusion

Humana reported $9.84 in diluted earnings per share for FY2025 — just 1.4% below the prior year. But the cash flow statement tells a different story. Operating cash flow collapsed from $2.97 billion to $921 million, a 69% decline that compressed the OCF/NI ratio from 2.46x to 0.78x. Humana generated 78 cents of cash for every dollar of reported profit, down from $2.46 the year before. This is the widest earnings-to-cash divergence in the company's recent history.

Management's explanation is concise. The filing attributes the entire decline to timing:

"The decrease in our operating cash flows primarily reflected timing impacts, including the year-over-year increase in receivables due to the IRA and the unfavorable impact of working capital items."

The receivables explanation is verifiable — and it falls short. Accounts receivable grew $566 million ($2.704 billion to $3.270 billion), reflecting the IRA's restructuring of CMS payment cycles. But $566 million explains only 28% of the $2.05 billion OCF decline [$566M / $2,045M]. The remaining 72% — approximately $1.48 billion — is attributed to "unfavorable impact of working capital items," a catch-all category that encompasses benefits payable timing, premium receipt cycles, and other operational movements. Unlike receivables, which have a clear reversal mechanism through CMS payment schedules, these working capital items may not normalize on a predictable timeline.

The capital allocation response confirms this is not business as usual. Buybacks collapsed 81.5%, from $817 million to $151 million. Dividends of $430 million exceeded free cash flow of $375 million, producing a dividend coverage ratio of just 0.87x. Total capital returned to shareholders ($581 million) consumed 155% of free cash flow — the shortfall funded by liquidating the investment portfolio, which drove cash nearly doubling from $2.2 billion to $4.2 billion. In March 2025, Humana issued $1.5 billion in new debt at rates between 5.55% and 6.0%, adding to the $12.4 billion in total borrowings.

This is not the capital allocation of a company experiencing a timing blip. It is the capital allocation of a company preparing for a siege. Humana's operating cash flow collapsed 69% to $921 million in FY2025, but accounts receivable growth of $566 million explains only 28% of the $2.05 billion decline — leaving $1.48 billion attributed to vague "working capital items" that may not reverse.

The Quarter the Full-Year Averages Conceal

Full-year financial statements average away the worst quarter. For Humana, that quarter was Q4 2025, and the gap between the annual average and Q4 standalone results is stark.

Deriving Q4 standalone results from the 10-K (full year) minus the 10-Q (nine months ended September 30, 2025) reveals a benefit ratio that spiked to approximately 92.9% — a midpoint estimate within a range of roughly 91.5% to 94.0%. This compares to the 89.3% average for the first nine months, a deterioration of approximately 360 basis points. The implied Q4 operating cost ratio rose to approximately 13.7%, derived by subtracting 9-month operating costs ($11.0 billion) from the full-year total ($15.5 billion) and dividing by Q4 revenue (~$32.8 billion). The resulting estimated combined ratio of approximately 106.6% means Humana was paying out more in medical claims and operating costs than it collected in premiums during the final quarter.

Q4 was also when management took its largest write-downs. Impairment charges totaled $253 million for the full year, but only $32 million was recorded through the first nine months. The remaining $221 million — including $96 million of indefinite-lived intangible impairments — landed in Q4 alone, signaling a reassessment of business unit values that was not apparent through Q3. Combined with $129 million of value creation (transformation) charges in Q4, total "one-time" items in the quarter reached $350 million.

The three-year pattern of "one-time" charges makes the Q4 surge harder to dismiss. Total non-recurring items have escalated from $527 million (2023) to $548 million (2024) to $769 million (2025) — averaging $615 million per year. At $769 million, FY2025's charges equaled 64.8% of reported net income ($1.188 billion). Management describes the transformation program as "multi-year," signaling additional charges ahead. For practical purposes, investors should treat approximately $600 million of annual charges as part of Humana's normalized cost base.

Humana's Q4 2025 benefit ratio spiked to approximately 92.9% — a roughly 360-basis-point deterioration from the first nine months' 89.3% average — producing an estimated combined ratio of 106.6% that indicates the company was losing money on insurance operations in the final quarter.

The $3.5 Billion Headwind vs. the 1.3 Million Member Gamble

The Star Ratings collapse is the single largest quantifiable risk in Humana's filing. Medicare Advantage plans rated 4-stars or higher declined from covering 94% of members (2024 payment year) to 25% (2025) to approximately 20% (2026). CMS quality bonus payments — formula-driven supplements of approximately 5% on capitation for 4+ star plans — represent an estimated $3.5 billion revenue headwind that exceeds Humana's entire FY2025 net income of $1.19 billion.

Humana's response is extraordinary: the company is suing its own regulator.

"We have filed a lawsuit that, among other things, seeks to set aside and vacate the 2025 Star Ratings for our Medicare Advantage plans, but there is no assurance that we will prevail."

Against this backdrop, management has made a bet that the filing's own membership data makes difficult to reconcile. In 2025, Humana deliberately exited "certain unprofitable plans and counties," reducing individual Medicare Advantage membership by 412,500 (-7.3%), from 5,661,800 to 5,249,300. This was framed as margin repair — pruning the costliest member cohorts.

For 2026, the strategy has completely reversed. Management guides approximately 25% individual MA membership growth — roughly 1.3 million new members to reach approximately 6.56 million — which would not only reverse the 2025 exits but add 900,000 members above the pre-exit base.

The central question is whether re-enrollment will be profitable. Two interpretations exist: either the 2025 exits successfully removed the worst-performing cohorts and the 2026 growth targets a healthier risk pool at better unit economics, or the massive Star Ratings revenue loss requires enrollment volume regardless of profitability — growth to offset a revenue hole, not to create margin.

The filing cannot resolve this question, but it does compound the uncertainty. The DOJ has intervened in a qui tam lawsuit alleging civil violations concerning "non-commission payments to broker partners" — targeting the very broker distribution channel that fuels MA enrollment. And CMS has accelerated RADV audits across Humana's entire Medicare Advantage contract base:

"CMS announced that it will conduct RADV audits for all eligible MA contracts for each payment year in all newly initiated audits and expedite the completion of RADV audits for PY 2018 through PY 2024 by early 2026."

Six years of potential retroactive payment adjustments, compressed into early 2026, with no dollar reserves disclosed — only "material adverse effect" language. Combined with the Star Ratings lawsuit and DOJ investigation, Humana faces a three-front regulatory assault while simultaneously attempting its largest membership expansion in recent history.

Humana's Star Ratings collapsed from 94% to 20% of Medicare Advantage members in 4+ star plans over two years, creating a roughly $3.5 billion quality bonus headwind that exceeds the company's entire FY2025 net income of $1.19 billion.

CenterWell — The Business Worth Owning Inside a Business Under Siege

If there is a structural bull case for Humana, it lives in CenterWell — the vertically integrated healthcare services segment encompassing primary care clinics, home health, and pharmacy operations. The segment data from the 10-K footnotes makes the case clearly.

CenterWell earned a 5.96% operating margin in FY2025, producing $1.339 billion of operating income from $22.5 billion in revenue. The Insurance segment, with $124.6 billion in revenue, generated $1.664 billion at a 1.34% margin. CenterWell's margin is 4.5 times Insurance's — and it is moving in the right direction. CenterWell's margin improved 17 basis points year-over-year, compared to Insurance's 4 basis points. Revenue grew 12.7% versus Insurance's 9.5%.

The result: CenterWell generates 44.6% of total segment operating income from just 17.3% of revenue. It is the tail wagging the dog — the smaller, higher-margin business cross-subsidizing the larger, razor-thin insurance operation.

But the math constrains the narrative. CenterWell's $1.34 billion in operating income would need to approximately double — to roughly $2.7 billion — to offset the estimated $3.5 billion Star Ratings headwind net of Insurance's contribution. At the current 12.7% revenue growth rate and improving margins, reaching that target implies five or more years of compounding. CenterWell is a long-term lifeline, not a near-term rescue.

The IRA's impact on the broader business adds context. Premium revenue grew 9.6% ($112.1 billion to $122.8 billion) despite the 7.3% membership decline, driven by higher per-member CMS subsidies under the Inflation Reduction Act. This per-member revenue lift supports the thesis that Humana's 2026 re-enrollment could generate more premium revenue per member than the exited cohorts. But benefits expense grew faster — up 10.1% to $110.8 billion — compressing the benefit ratio by 40 basis points to 90.2%.

Humana's CenterWell segment earned a 5.96% operating margin — 4.5 times the Insurance segment's 1.34% — generating 44.6% of segment operating income from just 17.3% of revenue, but its $1.34 billion operating income would need to roughly double to offset the Star Ratings headwind alone.

What to Watch

At $256 per share and 26 times trailing earnings, Humana's stock price embeds significant recovery assumptions. Managed-care peers trade at materially lower multiples — Elevance Health at 13.9x and Cigna at 12.3x are the most comparable pure-play MCOs, while UnitedHealth's 24.9x reflects its Optum diversification premium and CVS's 56.7x reflects depressed earnings. Anchoring to the ELV/CI range yields a peer-average multiple of approximately 13-14 times.

At 14x, Humana's current $9.84 EPS implies a stock price of approximately $138 — roughly half the current $256. To justify the current price at peer multiples, EPS would need to reach approximately $18.30 ($256 / 14), requiring nearly a doubling from current levels and more than a doubling from 2026 adjusted guidance of approximately $9.00. The filing shows EPS declining at a -17.2% five-year CAGR, with OCF quality impaired (0.78x OCF/NI) and a $3.5 billion headwind arriving.

The EV/EBITDA of 6.68x — cheapest in the managed-care peer group — appears to contradict the expensive P/E. But this divergence reflects Humana's heavy interest burden: $631 million in annual interest expense consumes 43.9% of pretax income ($631M / $1,438M). EBITDA flatters the picture by adding back interest; net earnings expose the reality for equity holders.

"The Final RADV Rule, including the lack of a FFS Adjuster, could each have a material adverse effect on our results of operations, financial position, or cash flows."

Three data points in Q1 2026 will determine whether the filing's deterioration is a temporary trough or a new baseline:

At $256, the market implies simultaneous success on Star Ratings recovery, OCF normalization, and profitable re-enrollment. The filing provides evidence that each is uncertain — but complicates a simple bearish view by showing CenterWell delivering margin expansion, the balance sheet deliberately fortified, and the IRA driving per-member revenue gains that could, under the right conditions, make re-enrollment profitable. Humana trades at 26 times trailing earnings versus a managed-care peer average of approximately 14 times, implying the stock price requires EPS to roughly double from $9.84 to justify the current $256 share price at industry-standard multiples.

Frequently Asked Questions

What caused Humana's operating cash flow to drop 69% in FY2025?

Management attributes the $2.05 billion decline (from $2.97 billion to $921 million) to "timing impacts, including the year-over-year increase in receivables due to the IRA and the unfavorable impact of working capital items." However, accounts receivable grew only $566 million — explaining just 28% of the OCF decline. The remaining 72% ($1.48 billion) is categorized as "working capital items," a broad term covering benefits payable timing, premium receipt cycles, and other operational movements. Whether this fully reverses in 2026 is the central cash flow question for investors.

Why did Humana's Star Ratings collapse, and how much does it cost?

Humana's Medicare Advantage plans rated 4-stars or higher declined from covering 94% of members (2024 payment year) to 25% (2025) to approximately 20% (2026). CMS quality bonus payments are formula-driven: 4+ star plans receive approximately 5% bonus payments on CMS capitation. For Humana's roughly 5.25 million individual MA members, this translates to an estimated $3.5 billion revenue headwind in 2026. Humana has filed a lawsuit seeking to vacate the 2025 Star Ratings, but its 10-K states "there is no assurance that we will prevail."

Is Humana's dividend safe?

At FY2025, Humana paid $430 million in dividends against $375 million in free cash flow — a coverage ratio of just 0.87x. The dividend is funded from the balance sheet ($4.2 billion cash) rather than ongoing cash generation. If OCF normalizes in 2026 (management's thesis), the dividend is safe. If Q4 2025's cash flow trajectory continues, the dividend would require ongoing balance sheet drawdowns or additional debt. Management has already slashed buybacks 81.5% ($817 million to $151 million) to preserve cash.

What is CenterWell and why does it matter for Humana investors?

CenterWell is Humana's vertically integrated healthcare services segment, encompassing primary care clinics, home health, and pharmacy. In FY2025, CenterWell generated $22.5 billion in revenue (17.3% of total) at a 5.96% operating margin — producing $1.34 billion of operating income, or 44.6% of total segment operating income. This is 4.5 times the Insurance segment's 1.34% margin. CenterWell's revenue grew 12.7% (versus Insurance's 9.5%) and its margin improved 17 basis points (versus Insurance's 4 basis points). For investors, CenterWell represents the long-term margin expansion story — but at current scale, it would need to roughly double earnings to offset the Star Ratings headwind.

Why is Humana's P/E ratio (26x) so much higher than peers like Cigna (12x) and Elevance (14x)?

The elevated P/E reflects compressed current earnings — net margin of 0.92% is the lowest among major MCOs except CVS, meaning the EPS denominator is suppressed — and the market pricing a recovery scenario where Star Ratings improve, OCF normalizes, and transformation savings emerge. At peer-average multiples of approximately 14x, the current $9.84 EPS implies a $138 stock price — roughly half the current $256. Either the market is right about a recovery, or HUM is significantly overvalued relative to current fundamentals.

What does RADV mean for Humana, and how big is the risk?

Risk Adjustment Data Validation (RADV) is CMS's audit program verifying that Medicare Advantage insurers accurately reported the health conditions of their members, which determine capitation payments. CMS announced it will audit ALL eligible MA contracts for payment years 2018-2024, accelerated to complete by early 2026. Humana discloses no dollar reserves for RADV exposure, using only "material adverse effect" language — the strongest disclosure threshold short of quantified exposure. A court vacated the RADV Rule as procedurally invalid, but the ultimate outcome remains uncertain. This creates six years of potential retroactive payment adjustments that cannot currently be quantified.

Why did Humana exit MA plans in 2025 and then reverse course for 2026?

In 2025, Humana deliberately exited "certain unprofitable plans and counties," reducing individual MA membership by 412,500 (-7.3%). This was framed as margin repair — removing the costliest member cohorts. For 2026, management guides approximately 25% individual MA membership growth (~1.3 million new members), completely reversing course. Two interpretations exist: (1) the exits successfully pruned the worst performers, and re-enrollment targets a healthier risk pool at better unit economics, or (2) the massive Star Ratings revenue loss requires enrollment growth regardless of profitability, prioritizing top-line scale over margin. Q1 2026 enrollment plus benefit ratio data will distinguish between these interpretations.

Are Humana's "one-time" restructuring charges actually recurring?

Over three years, total "one-time" items have been: $527 million (2023), $548 million (2024), and $769 million (2025) — averaging $615 million annually. At $769 million in FY2025, these charges equal 64.8% of reported net income ($1.188 billion). Management describes the transformation program as "multi-year," suggesting additional charges in 2026 and beyond. For practical purposes, investors should treat approximately $600 million of annual charges as part of Humana's normalized cost base until the program explicitly ends.

How does Humana's cash flow quality compare to other managed care companies?

Humana's OCF/NI ratio collapsed from 2.46x in FY2024 to 0.78x in FY2025 — the most severe deterioration among major MCOs. Elevance Health experienced a similar directional decline (0.97x to 0.76x). UnitedHealth and Cigna also showed cash flow pressure. The industry-wide trend reflects rising medical utilization and IRA-related payment timing, but Humana's magnitude ($2.05 billion OCF decline) is the largest in both absolute and relative terms among managed care peers.

What would it take for Humana's stock to justify its current $256 price?

At 26x P/E, justification at managed-care peer average multiples (approximately 14x) requires EPS of approximately $18.30 — roughly double the current $9.84 and more than double the 2026 adjusted guidance of approximately $9.00. This requires simultaneous success on three fronts: (1) Star Ratings recovery to 4+ stars within 2-3 years, restoring roughly $3.5 billion of quality bonus payments; (2) OCF normalization above $2.5 billion, proving the "timing" thesis correct; and (3) successful re-enrollment at profitable unit economics. The filing provides evidence that each of these is uncertain.

What is the IRA's impact on Humana's financials?

The Inflation Reduction Act redesigned the Medicare Part D prescription drug benefit, including direct government subsidies for certain costs. For Humana, the IRA drove two effects: (1) higher per-member Medicare premiums, which was the primary driver of the 9.6% premium revenue growth ($112.1 billion to $122.8 billion), and (2) a timing mismatch in receivables as CMS payment cycles adjusted to the new subsidy structure, contributing to the $566 million accounts receivable increase. Management uses the IRA as the primary explanation for the OCF decline, though the data shows it directly explains only about 28% of the cash flow deterioration.

Is Humana at risk of a credit downgrade?

Humana's debt-to-capitalization moved from 40.3% (September 2025) to 41.1% (December 2025), an 80 basis point deterioration in a single quarter during which operating income was deeply negative. Total debt stands at $12.4 billion with interest coverage of 4.29x. Interest expense of $631 million consumes 43.9% of pretax income. The $5.0 billion revolving credit facility ($4.99 billion available) provides near-term liquidity buffer, and no debt matures within 12 months. However, the combination of rising debt levels ($1.5 billion issued March 2025 at 5.5-6.0%), deteriorating operating cash flow, and Q4's operating loss trajectory creates conditions where a downgrade becomes plausible if 2026 operating results do not improve.

What is Humana's Q4 2025 benefit ratio and why does it matter?

By subtracting 9-month results (from the 10-Q) from full-year figures (from the 10-K), the Q4 2025 benefit ratio is estimated at approximately 92.9% — a midpoint within a range of roughly 91.5% to 94.0%. This compares to the 89.3% average for the first nine months, a deterioration of approximately 360 basis points. The implied combined ratio of approximately 106.6% means Humana was paying out more in medical costs and operating expenses than it collected in premiums during Q4. Whether Q4 represents seasonal noise (open enrollment costs) or the new baseline is the single most important question for 2026 earnings.

Methodology

Data Sources

This analysis uses three data sources, each tagged for traceability:

• MetricDuck Metrics Pipeline [PIPELINE]: Core financial metrics (income statement, balance sheet, cash flow, returns, valuation) from automated SEC filing extraction. Available at HUM Analysis.
• SEC 10-K Filing [FILING]: Verbatim quotes and detailed disclosures from Humana's FY2025 Annual Report, filed February 19, 2026, including MD&A, risk factors, and segment footnotes. The Q3 2025 10-Q (nine months ended September 30, 2025) was used for the Q4 standalone derivation.
• Derived Calculations [DERIVED]: Key formulas include: receivables as percentage of OCF decline ($566M / $2,045M = 28%), Q4 revenue (~$129.7B full-year minus ~$96.9B nine-month = $32.8B), Q4 benefit ratio ($28.7B benefits / ~$30.9B premiums = 92.9%), Q4 operating cost ratio ($4.5B / ~$32.8B = ~13.7%), Q4 combined ratio (~92.9% + ~13.7% = ~106.6%), FCF dividend coverage ($375M / $430M = 0.87x), capital returned to FCF ($581M / $375M = 155%), CenterWell margin spread (5.96% / 1.34% = 4.5x), and implied peer-average P/E (~14x, anchored by ELV at 13.9x and CI at 12.3x). All peer metrics are FY2025 actuals.

Limitations

• Q4 standalone derivation is an estimate. The Q4 benefit ratio (~92.9%) is derived by subtracting 9-month YTD figures from full-year totals. Both inputs are rounded, producing an approximate range of 91.5% to 94.0%. Q4 seasonality (open enrollment costs) naturally elevates operating costs, but the magnitude of deterioration exceeds typical seasonal patterns.
• No quarterly OCF disclosure. Only annual OCF is reported. Q4 cash burn is inferred from directional signals (negative operating income, impairment timing) but cannot be confirmed precisely.
• Star Ratings revenue impact is estimated. The $3.5 billion figure is a widely cited estimate based on CMS quality bonus formulas applied to Humana's membership. It is not a Humana-disclosed figure.
• 2026 EPS guidance ($9.00 adjusted) is from the earnings call, not confirmed in the 10-K text. The filing provides membership guidance but not margin or EPS guidance.
• No benefit ratio by line of business. The consolidated 90.2% is the only disclosure. State-based contracts and Part D plans carry higher benefit ratios; the individual MA standalone benefit ratio is not broken out.
• Peer comparison context. UNH, ELV, CI, and CVS are referenced for context. All peer metrics are FY2025 actuals from MetricDuck pipeline data. UNH ROE is N/A due to negative equity.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in HUM, UNH, ELV, CI, or CVS. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.